Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...

Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also underperformed in the sector and the S&P 500 during the same time ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

LONDON, March 27 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...